| Symbol | AKTX |
|---|---|
| Name | AKARI THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 75/76 WIMPOLE STREET, LONDON, W1G 9RT, United Kingdom |
| Telephone | +44 2080040270 |
| Fax | — |
| — | |
| Website | https://www.akaritx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001541157 |
| Description | Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom. Additional info from NASDAQ: |
Farag Kameel D. 🟢 acquired 1.7K shares of Akari Therapeutics Plc (AKTX) at $7.52 Transaction Date: Aug 17, 2026 | Filing ID: 039246
Read moreAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Read moreAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Read more(10% Negative) AKARI THERAPEUTICS PLC (AKTX) Reports Q3 2026 Financial Results
Read moreNew Form SCHEDULE 13G - Akari Therapeutics Plc <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000927971-26-000091 <b>Size:</b> 1 MB
Read moreNew Form SCHEDULE 13G - Akari Therapeutics Plc <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001952614-26-000004 <b>Size:</b> 8 KB
Read moreAkari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Read moreAkari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Read moreAkari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Read moreDirector Patel Samir Rashmikant 🟢 acquired 44.9K shares (3 derivative) of Akari Therapeutics Plc (AKTX) at $8.00 Transaction Date: Jul 07, 2026 | Filing ID: 033634
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05061771 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct O… | Phase3 | Bullous Pemphigoid | Withdrawn | 2022-05-06 | 2022-08-01 | ClinicalTrials.gov |
| NCT04784455 | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Phase3 | Thrombotic Microangiopathies | Terminated | 2021-02-01 | 2024-05-15 | ClinicalTrials.gov |
| NCT04037891 | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis | Phase1 | Keratoconjunctivitis, Atopic | Terminated | 2019-03-04 | 2020-04-30 | ClinicalTrials.gov |
| NCT04035733 | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Phase2 | Bullous Pemphigoid (BP) | Completed | 2018-09-25 | 2020-04-29 | ClinicalTrials.gov |
| NCT03588026 | Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 | Phase3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2018-06-07 | 2020-09-03 | ClinicalTrials.gov |
| NCT03427060 | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 … | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2018-05-14 | 2021-02-03 | ClinicalTrials.gov |
| NCT03829449 | rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2017-03-13 | 2020-08-29 | ClinicalTrials.gov |
| NCT02591862 | Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase2 | Paroxysmal Nocturnal Haemoglobinuria (PNH) | Completed | 2016-02-01 | 2018-03-20 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Coversin | Other | Phase PHASE2 | Paroxysmal Nocturnal Haemoglobinuria (PNH) | COMPLETED | NCT02591862 |
| Placebo | Other | Phase PHASE3 | Bullous Pemphigoid | WITHDRAWN | NCT05061771 |
| nomacopan (rVA576) | Other | Phase PHASE3 | Bullous Pemphigoid | WITHDRAWN | NCT05061771 |
| Standard of care (SOC) | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03588026 |
| rVA576 | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03588026 |
| Placebo | Other | Phase PHASE1 | Keratoconjunctivitis, Atopic | TERMINATED | NCT04037891 |
| rVA576 | Other | Phase PHASE1 | Keratoconjunctivitis, Atopic | TERMINATED | NCT04037891 |
| rVA576 | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT03829449 |
| rVA576 | Other | Phase PHASE2 | Bullous Pemphigoid (BP) | COMPLETED | NCT04035733 |
| Coversin | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03427060 |
| nomacopan (rVA576) | Other | Phase PHASE3 | Thrombotic Microangiopathies | TERMINATED | NCT04784455 |